ANI PHARMACEUTICALS INC: 2H26 Setup Favorable w/ Cortrophin Ramping & Conservative EBITDA – Reit OW

研报英文原文证据摘录

ANI PHARMACEUTICALS INC: 2H26 Setup Favorable w/ Cortrophin Ramping & Conservative EBITDA – Reit OW

ication (including third-party data) has been obtained from sources

that Barclays Research believes to be reliable, but Barclays does not represent or warrant that it is accurate or complete. Third-party data, including

third-party forecasts and predictions, is provided for information purposes only, has not been adopted or endorsed by Barclays, and does not

represent the views or opinions of Barclays. Presentations by Third-Party Speakers: Any views or opinions expressed by third-party speakers during a

Barclays-hosted event are solely those of the speaker and do not represent the views or opinions of Barclays. Barclays is not responsible for, and

makes no warranties whatsoever as to, the information or opinions contained in any written, electronic, audio or video presentations by any third-

party speakers, and such presentations have not been adopted or endorsed by Barclays and do not represent the views or opinions of Barclays.

Content from third-party presentations is provided for information purposes only and has not been independently verified by Barclays for its accuracy

or completeness.

The views in this publication are solely and exclusively those of the authoring analyst(s) and are subject to change, and Barclays Research has no

obligation to update its opinions or the information in this publication. Unless otherwise disclosed herein, the analysts who authored this report have

not received any compensation from the subject companies in the past 12 months. If this publication contains recommendations, they are general

recommendations that were prepared independently of any other interests, including those of Barclays and/or its affiliates, and/or the subject